Topic: Genentech Inc.
The Medical Affairs function arguably plays the most critical role in a biopharmaceutical organization, with heavy responsibilities across areas...
The speculation earlier this week that Roche was planning a round of cutbacks is, in fact, on the money. After a scheduled managerial meeting, the...
The ASCO Post captured initial reactions to the Oncologic Drugs Advisory Committee (ODAC) recommendation that the breast cancer indication for...
Sees Q3 rev of $86 mln vs est $83.6 mln. . * Says responds to Genentech patent letter. . * Says files complaint against Genentech in Nevada court...
A joint advisory committee of the U.S. Food and Drug Administration overwhelmingly voted against the approval of Jazz Pharmaceuticals' (JAZZ) drug...
In a surprising move, the FDA late last week issued a Refuse to File letter to Roche's Genentech unit for its T-DM1 biologic, which is being...
ImmunoGen (IMGN) is a Waltham, Massachusetts based biotechnology company. On Friday August 27th, 2010, their collaborative partner Genetech, a...
Shares of Waltham biotechnology company ImmunoGen Inc. plunged 38.5 percent yesterday after US regulators rebuffed a bid to gain fast-track status...
WASHINGTON (Reuters) - The U.S. Food and Drug Administration has released its latest list of possible drug safety concerns, citing Roche's breast cancer drug Herceptin and Sanofi Aventis' heart drug Multaq, among others.The list, which comes out quarterly
FDA denies accelerated approval for ImmunoGen, Genentech potential breast cancer treatmentFederal regulators have ruled that a potential breast cancer treatment from ImmunoGen failed to meet the standard for accelerated approval, the company said Friday.T